MedTrace Logo

Clinical Study of Sanjin Tablets for the Treatment of Acute Simple Lower Urinary Tract Infection

NCT03658291 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2018-11-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and immune mechanism of Sanjin tablets for the treatment of acute simple lower urinary tract infection and its influence on recurrence rate.

Conditions

  • Urinary Tract Infection Lower Acute

Interventions

DRUG

Sanjin tablets

Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.

DRUG

Sanjin tablets simulants

levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.

DRUG

Levofloxacin

Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.

Sponsors & Collaborators

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences

    collaborator OTHER

  • Shanghai University of Traditional Chinese Medicine

    collaborator OTHER

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Hubei Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Chengdu University of Traditional Chinese Medicine

    collaborator OTHER

  • Yunnan Provinical Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Yanming Xie, BA · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-06-30
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03658291 on ClinicalTrials.gov